Anaptysbio (ANAB) Receivables (2016 - 2026)
Anaptysbio's (ANAB) quarterly Receivables came in at $25.7 million in Q1 2026, up 43.97% YoY from $17.9 million in Q1 2025, and down 23.94% on a QoQ basis from $33.8 million in Q4 2025.
Anaptysbio (ANAB) Receivables (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Receivables data on file, last reported at $25.7 million in Q1 2026.
- Quarterly Receivables rose 43.97% year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (up 43.97% YoY) and the FY2025 annual result came in at $33.8 million, down 16.96% from the prior year.
- Receivables fell to $25.7 million in Q1 2026, from $33.8 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $75.7 million in Q3 2025 to a low of $921000.0 in Q1 2022.
- A 5-year average of $15.5 million and a median of $7.1 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables dropped 26.14% — and 2025, when it jumped 520.62%.
- Tracing ANAB's Receivables over 5 years: stood at $1.4 million in 2022, then soared by 382.8% to $6.9 million in 2023, then soared by 495.02% to $40.8 million in 2024, then fell by 16.96% to $33.8 million in 2025, then retreated by 23.94% to $25.7 million in 2026.
- The last three Receivables figures came in at $25.7 million (Q1 2026), $33.8 million (Q4 2025), and $75.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 25.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.75 Mn |
| Dec 31, 2025 | 33.85 Mn |
| Sep 30, 2025 | 75.69 Mn |
| Jun 30, 2025 | 21.42 Mn |
| Mar 31, 2025 | 17.88 Mn |
| Dec 31, 2024 | 40.77 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Jun 30, 2024 | 9.01 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 6.85 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 3.18 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 1.42 Mn |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 921,000.00 |
| Dec 31, 2021 | 876,000.00 |
| Sep 30, 2021 | 761,000.00 |
| Jun 30, 2021 | 642,000.00 |